# Integrative Oncogenomics of Multiple Myeloma

> **NIH NIH P01** · DANA-FARBER CANCER INST · 2020 · $2,065,928

## Abstract

Project Summary (Overall)
This renewal application stems from our successful first four years of a new program project grant funded in
2011, which brings together a talented group of investigators with expertise in basic biology (DFCI and
Whitehead Institute at MIT), clinical science (IFM), as well as genomic and cell signaling (Sanger Institute UK
and DFCI). During the prior 4 years of funding period, we have 1. defined the role of transplant in the era of
novel agents; 2 Established the role of molecular minimal residual disease (MRD) in myeloma. 3. Established
the role of both MRI and PET/CT in diagnosis and follow up of MM patients. 4. Identified and Validated number
of novel targets. and 5. Defined patterns of clonal evolution and mutational signatures being utilized in MM.
Our program has also developed novel targeted sequencing platform, developed a pipeline to identify
mutations using RNA-seq, and developed a publicly available data analysis portal (Canevolve.org). Building on
these advances, The overall specific objectives of the program are 1) To determine whether maintenance can
be tailored based upon MRD status and whether achieving MRD negative status provides superior outcome In
a 1260 patient randomized clinical study and to develop novel risk model (Project 1). Clinically annotated
patient samples from this clinical trial will be utilized to study genomic and epigenomic correlates; 2) To identify
the spectrum of epigenomic lesions and enhancer dependencies that underlie pathogenesis, progression, and
clinical outcome in MM. (Project 2). New clinically-relevant epigenomic-centered targets identified will be
validated further; 3) To identify and validate the molecular circuits/loops responsible for continued MM cell
growth and develop strategies to interrupt these loops as a novel therapeutic approach. (Project 3). New
targeted therapeutic agents will be translated to clinical trials to improve patient outcome; and 4) To define the
impact of therapy on clonal evolution and identify mediators of genomic instability underlying disease prognosis
and progression in MM (Project 4). New clinically relevant processes identified will be used to understand
process of progression. These 4 projects will be supported by Administrative and Communication Core (1),
Clinical and Tissue Core (2); Genomics Core (3); Genomic Sequencing Core (4) and Biostatistical and
Bioinformatics Cores (5). This unique collaborative effort will improve our understanding of myeloma biology
and define a new treatment paradigm for this presently incurable disease.

## Key facts

- **NIH application ID:** 9987267
- **Project number:** 5P01CA155258-09
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** Nikhil C. Munshi
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $2,065,928
- **Award type:** 5
- **Project period:** 2011-12-01 → 2022-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9987267

## Citation

> US National Institutes of Health, RePORTER application 9987267, Integrative Oncogenomics of Multiple Myeloma (5P01CA155258-09). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9987267. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*